Skip to main content
. 2021 Feb 12;11(2):471. doi: 10.3390/nano11020471

Scheme 1.

Scheme 1

Schematic of the immune checkpoint blockade (ICB) antibody releasing hydrogel for antitumor therapy. ICB antibodies are released from intradermally injected hydrogels in a sustained manner. As a result, the benefits of ICB for T cell instruction are prolonged, improving the anti-tumor effects of ICB immunotherapy.